2025 Poster Presentations Coming in October
Here is a reminder of the 2024 posters:
POSTER SESSION A: Tuesday - Wednesday (morning)
*Posters 001-011 will be in both Poster Sessions and available Wednesday only.
*A001: Glyoxal Agarose as the Best Alternative for Covalent Antibody Coupling in Affinity Chromatography, Presented by Yaiza L., Agarose Bead Technologies
*A002: IgBlend: Unifying 3D Structure and Sequence for Antibody LLMs, Presented by Cedric M., AstraZeneca
*A003: Novel LCMS-Compatible icIEF Fractionation for Characterization of Innovator and Biosimilar mAbs, Presented by Jean-Francois B., Bio-Techne
*A004: Advancing Drug Discovery Using mMPS High-Throughput Synthesis Technology to Elevate Variant Library Precision, Presented by Ming D., GCATbio Co., Ltd.
*A005: Biology42: Generative Biologics Is an Advanced, AI-Powered Platform that Is Capable of Designing and Optimizing Different Types of Biologics, Including Peptides, Nanobodies, and Antibodies Tailored for Specific Targets, Presented by Andrei A., Insilico Medicine AI
*A006: K-One® Innovative Surface Chemistry: Revolutionizing Chip Functionalization and SPR Analysis of Biotherapeutics, Presented by Nicolas H., Kimialys
*A007: Unlocking Anakinra’s Potential: PEGylation for Prolonged Stability and Chain-length Modulation, Presented by Isilay G., Koc University
*A008: Broadly Inhibitory Human Monoclonal Antibodies Against Duffy Binding Protein II Variants Elicited by Natural Plasmodium vivax Infection, Presented by Piyawan K., Mahidol University
*A009: Combination of Peptide Mapping Analysis and SPR-Based Binding Kinetic to Identify Methionine Oxidation and Its Effect on the Biological Activity of IgG1 Antibody, Presented by Elvira L., Menarini Biotech S.r.l.
*A010: In Vivo Reprogramming of CAR-T Cells with LNP-Circular RNA Technology, Presented by Jing Z., Therorna, Inc.
*A011: A Clickable Antibody Design to Generate Antibody-Drug Conjugates (ADCs) in a Trojan Horse Manner, Presented by Nathanael R., Universitat Ramon Llull
A012: Real-Time Kinetics on Cells and Further Analytical Tools to Avoid the Translational Gap, Presented by Vera M., 2bind GmbH
A013: New Epitope Mapping Combines Single Amino Acid Resolution and High Throughput: SEQITOPE, Revolutionizing the Antibody Selection Process, Presented by Mats P., AAX Biotech AB
A014: Discovering Site-Specific Antibodies Against Challenging Targets Using the Epivolve Platform, Presented by Troy L., AbbraTech, Inc.
A015: Biophysical Methodologies for the QC of Abcam Rabbit Monoclonal Antibodies (RabMAb®) and Proteins, Presented by Fiona T., Abcam plc
A016: Discovery of Diverse GPCR-Targeted Antibodies Using Integrated Technologies, Presented by Romain R., AbCellera Australia
A017: Plug-and-Play Approach to Stabilize scFv Fragment Antibodies, Presented by Greg D., AC Immune
A018: Accelerating the Development of Novel Antibody-Drug Conjugates Through Site-Specific Conjugation Methods, Presented by Hengshuo L., ACROBiosystems
A019: Analysis of NIST mAb Reference Material by Parallel SDS-Capillary Electrophoresis, Presented by Xuemei L., Agilent Technologies
A020: Enhancing the Cytotoxicity of Immunotoxins by Facilitating Their Dissociation from Target Receptors Under the Reducing Conditions of the Endocytic Pathway, Presented by Byeong-Ho C., Ajou University
A021: ANV600 Is a Novel PD-1 Targeted IL-2Rß/γ Agonist that Is Combinable with Therapeutic PD-1 Inhibitors, Presented by Christian S., Anaveon AG
A022: CIS Display 2.0: An In Vitro Display Technology for Complex Microprotein Discovery, Presented by Duncan M., Applied Biomedical Science Institute
A023: Leap-In Transposases® - A New Standard in Cell Line Development, Presented by Mario P., ATUM
A024: Rapid Generation of Bispecific Antibodies for High-Throughput Screening with SpyLock Technology, Presented by John C., Bio-Rad Laboratories
A025: TrailBlazer: A Rapid Modular Antibody Assembly Platform, Presented by Sophie M., Bio-Rad Laboratories
A026: Pioneer Platform: A Novel Biotherapeutic Antibody Discovery Platform, Presented by Paul R., Bio-Rad Laboratories
A027: Separation of Bispecific-Antibody Related Impurities with Mixed-Mode Chromatography, Presented by Artur S., Bio-Rad Laboratories
A028: Characterization of the FcRn-Doppelmab Interaction via a Combination of Affinity Chromatography and Mass Spectrometry, Presented by Miriam E., Boehringer Ingelheim Pharma GmbH & Co. KG
A029: High-Throughput Protein Quality Attribute Monitoring During Biotherapeutics Development by MALDI-MS, Presented by Christopher l., Boehringer Ingelheim Pharma GmbH & Co. KG
A030: TheraPRO® CHO Media System: Achieve High Productivity in CHOK1SV GS-KO® Cell Lines with Our Advanced Formulated, Easy-to-Use Media and Feed Solution, Presented by Joke S., Lonza Benelux BV
A031: Formulation Development - New Platform Concept, Presented by Mihaela S,, Boehringer Ingelheim Pharma GmbH & Co. KG
A032: Going Beyond Binary Hit Generation with Opto® B Discovery Affinity Assay on the Beacon® Optofluidic System, Presented by Tiago S., Bruker
A033: Digital Control of Expression for Rapid, High-Titer Production of Complex Products in CHO Cells, Presented by Laura D., Catalent
A034: Tumbler: A Highly Customizable Antibody Optimization Suite, Presented by Brad G., Charles River Laboratories
A035: Retrogenix® Express Off-Target Panel: Rapid Early Assessment of Off-Target Binding in Phage Display Platforms, Presented by Diogo R., Charles River Laboratories
A036: Rapid Immunogenicity Screening of Antibody Therapeutics via Human CD4+ T Cell IL-2 Secretion, Presented by Yoshiyuki A., Chugai Pharmaceutical Co., Ltd.
A037: Drug Product Oriented mAb Developability Assessment Combining Biophysical Characterization and Benchmarking to Commercial Products, Presented by Kristian L., Coriolis Pharma
A038: Automated Image Analysis AI Model of Ice Crystal Growth for Optimization of Annealing in Lyophilization, Presented by Kanako M., Daiichi Sankyo Co., Ltd.
A039: Developing Protein Engineering for Defence and Security, Presented by Josh P., Defence Science and Technology Laboratory (Dstl)
A040: Antibody Characterization Before Cloning Is the Key: Advanced DIANA HTS Monoclonal Antibody Discovery Pipeline, Presented by Klara K., DIANA Biotechnologies, a.s.
A041: Improving Biopharmaceutical Processes Through Raman Spectroscopy-Driven Automated Monitoring and Control, Presented by Lydya AM., Endress+Hauser
A042: Droplet Microfluidic Antibody Screening Platform for Functional Antibodies at the Single-Cell Level, Presented by Leonie K., EPFL - Swiss Federal Institute of Technology Lausanne
A043: CD2 BiTco: Novel CD2-Targeted Bispecific T Cell Co-Stimulators for Cancer Immunotherapy, Presented by Welbeck D., Evotec International GmbH
A044: Mytomab: Multi-Specific Cytotoxicity Maximizing Antibodies for Cancer Immunotherapy, Presented by Gerhard N., Evotec International GmbH
A045: Use of Drosophila S2 Cells for Production of Highly Immunogenic Antigens, Presented by Max S., ExpreS2ion Biotechnologies
A046: Accelerating Antibody Discovery and Development to the Clinic with Proprietary Mammalian Display, Presented by Cleide F., FairJourney Biologics SA
A047: FcRN Binding Assessment of IgG Fc Variants: A 360° View with Affinity, Kinetics and In Vitro Testing, Presented by Rita M., FairJourney Biologics SA
A048: Continuous Titration Based Method for Rapid In-Solution Analysis of Non-Covalent Interactions, Presented by Philipp W., Fida Biosystems ApS
A049: Ab-ility™ - An In-Silico Analysis and Developability Engineering Platform, Presented by Britney A., Fusion Antibodies plc
A050: Integrated Analysis of Assays Drives Early Developability Assessment of Antibodies, Presented by Miguelangel CV., Genedata AG
A051: End-To-End Software Platform for Streamlined LC/MS-Based Multi-Attribute Method (MAM) Implementation, Presented by Catherine E., Genedata AG
A052: A Digital Platform to Automate Production, Optimization, and Evaluation of Viral and Non-Viral Vectors for Cell and Gene Therapy, Presented by Sebastian K., Genedata AG
A053: Automatic Assignment of Biacore SPR and Octet BLI Kinetic Binding Curve Profiles with Artificial Intelligence, Presented by Maija P., Genedata AG
A054: Antibody and Therapeutics Discovery: Network and Tree Visualizations for Interrogating Sequence Similarity Between Unique Clones and CDRs in NGS Datasets, Presented by Evan S., Geneious by Dotmatics
A055: High Throughput Expression Strategies for Protein Complexes, Presented by Angita S., GlaxoSmithKline
A056: Developing Pineal Cell Lines for Sleep Drug Screening, Presented by Hong L., Humetacell Co., Ltd.
A057: Purification of In Vivo Biotinylated Proteins by Using Strep-Tactin®XT, Presented by Philipp H., IBA Lifesciences GmbH
A058: Development of Therapeutic Antibodies Targeting the GLUT1 Transporter to Restrict Cancer Cell Growth, Presented by Lauri P., Icosagen
A059: BTN2A1 Targeting Reprograms M2-Like Macrophages and TAMs via SYK and MAPK Signaling, Presented by Carla C., ImCheck Therapeutics
A060: Immunotoxicity Assessment of Clinical Antibodies Using an Ex Vivo Circulating Human Whole Blood Assay with Low Anticoagulants, Presented by Laura R., Immuneed AB
A061: Generate Your Single-Domain Antibodies (VHH) in 6 Weeks Using AI and Biological Tools, for Impactful Research, Presented by Philippe H., Immunochem
A062: Optimizing Discovery Strategies for TCR Bispecific, Presented by Sam E. & Peter M., Immunocore Ltd.
A063: Site-Specific Integration of Transgenes into CHO Cells Using Landing Pads, Presented by Tobias M., InSCREENeX GmbH
A064: Site-Directed Cysteine Conjugation of Disulfide-Rich Non-Antibody Carrier Proteins (THIOCAPs) for Targeted Cancer Therapies, Presented by Ugutz U., Institut de Recerca Sant Pau (IIB St Pau)
A065: Lipoparticles (VLPs) Present Native-Conformation Membrane Proteins, Enabling Antibody Discovery, Presented by Ross C., Integral Molecular
A066: Specificity Testing of Antibodies, Multispecifics, and CAR-T Therapeutics for IND Using the Membrane Proteome Array, Presented by Rachel F., Integral Molecular
A067: Replacing Live Virus in Bioassays – Reporter Virus Particles (RVPs), Presented by Ileine S., Integral Molecular
A068: Unleashing the Power of MHC-Associated Peptide Proteomics: Immunogenicity Assessment of Biotherapeutics, Presented by Sofie P., IQVIA Laboratories
A069: Synergistic Effect of Human-Like Monoclonal Antibodies in Poxvirus Protection, Presented by Hadas T., Israel Institute for Biological Research
A070: In-Silico Solutions for Accelerated and Enhanced Antibody Discovery and Development, Presented by Marianne BS., JSR Life Sciences
A071: Tailored AAV Solutions: AAV ELISA Kits and Customized Variant Kit Development, Presented by Yujiao Z., KactusBio, Inc.
A072: Comprehensive and Reliable Characterization of Antibody Therapeutics Thanks to K-One® Powered Innovative SPR Biochips, Presented by Adrien A., Kimialys
A073: Highly Efficient Capture of Circulating and Tissue-Infiltrating B Cell Repertoires from Multiple Species: Kling-Select, Presented by Casper M., Kling Biotherapeutics BV
A074: Kling-Evolve as a Tool for Rapid Response to Emerging Variants and Pandemic Preparedness: Directed Evolution of Variant-Specific Antibody from Immortalized B Cells, Presented by Casper M., Kling Biotherapeutics BV
A075: Rational Design and Optimization of an IL-6 Binding Nanobody Through CDR Grafting and Mutagenesis, Presented by Chandana S., Korea Research Institute of Bioscience and Biotechnology
A076: Design of an Affibody-Peptide Fusion for Inhibition of Sortilin-Mediated Progranulin Degradation, Presented by Moira E., KTH Royal Institute of Technology
A077: A Drop of Insight: Single Cell Functional Profiling for Immunotherapy, Presented by Simon M., Lightcast
A078: Identification of Next-Generation Brain Shuttles and Shuttle Targets and Using Multiplexed In Vivo Screening with Protein Barcodes, Presented by Karen D., Manifold Bio
A079: Visualizing Antibody-Receptor Interactions at Single-Protein Resolution with RESI, Presented by Isabelle P., Max Planck Institute of Biochemistry
A080: MHC MACSimers Combine Flexibility, Quality and Releasability for the Detection of Ag-Specific T Cells, Presented by Marek W., Miltenyi Biotec B.V. & Co. KG
A081: Combination Screening Approaches of Novel Synthetic Single Domain Antibody Library, Presented by Cameron S., Monash University
A082: Development of a ‘Switchable’ Yeast for Antibody Discovery, Presented by David I., Neochromosome, Inc.
A083: Optimization of pIX Phage Display for Improved Discovery of Human TCR-Like Antibodies, Presented by Goril B. & Terje F., Nextera AS
A084: A Novel icIEF and Digital SPR Workflow for Correlating the Charge Structure to the Function of a Bispecific Antibody, Presented by Anja M., Nicoya Lifesciences
A085: Single Domain CD3 Antibody Enables Next-Generation T Cell Engagers for Enhanced Immunotherapies, Presented by Xiangyu R., Nona Biosciences
A086: Pre-Clinical Validation of Humanized Bicistronic CAR T Cells Against CCR9 and CD1a for the Treatment of Relapsed/Refractory T-Cell Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma (T-ALL/LL), Presented by Alba GP., OneChain Immunotherapeutics
A087: Using Mammalian Display to Mature Anti-AGelD187N Antibody for Subcutaneous Delivery, Presented by Laura L., Orion Corporation
A088: Developability Assessment for Nonspecificity and Polyspecificity in High-Throughput Bead-Based Assays in Microplates, Presented by Sebastian G., PAIA Biotech GmbH
A089: Imaging Mass Cytometry Reveals the Spatial Network of Immune Cells in Neuroblastoma, Presented by Francisca B., Prinses Maxima Centrum
A090: A Game of Hide and Seek: Targeting Neuroblastoma's Escape from Immunotherapy, Presented by Beatrice P., Prinses Maxima Centrum
A091: Development of Bioluminescent No-wash Fc Gamma Receptor Binding Immunoassay to Guide the Development of Antibody Therapeutics, Presented by Kai H., Promega Corporation
A092: Improved Analytical Methodologies for the Characterization of Biosimilars, Presented by Michael R., Promega Corporation
A093: Advancements in Multi-Protein Quantitation for Host Cell Protein Discovery, Presented by Stephane B., Protein Metrics by Dotmatics
A094: A Middle-Level Approach to Simplify Sample Preparation and Data Analysis for Characterization of the Fusion Protein Blinatumomab, Presented by Lucy F., Protein Metrics by Dotmatics
A095: Digested Oligonucleotide IP-RPLC-MS/MS Characterization of mRNA Sequence, 5’ Cap, and 3’ PolyA Tail, Presented by David L., Protein Metrics by Dotmatics
A096: Advancing Antibody Engineering and Maturation with High-Throughput Single-Molecule Imaging System, Presented by Booyoung Y., PROTEINA Co., Ltd.
A097: Structural Basis for the FLAG/Anti-FLAG M2 Interaction, Presented by Matti P., QVQ Holdings B.V.
A098: Improving Antibody Fragment Expression in Escherichia coli for the Generation of Smart Targeted Therapeutics, Presented by Montserrat ER., Ramon Llull University
A099: Optimizing a Mammalian Cell-Free Expression System Using Design of Experiments, Presented by Maximilian G., RWTH Aachen University
A100: Novel Human and Murine Monoclonal Antibodies Targeting CDH17 in Tumors, Presented by Sherry C., Sanyou Biopharmaceuticals, Inc.
A101: Protein-Based Therapeutics: Leveraging NMR for Formulation Optimization, Quality Control, and Biosimilar Development, Presented by Anais N., SARomics Biostructures AB
A102: Verification of the Unique Functionality of ATOR-1017 by 3D Structure Determination, Presented by Megan S., SARomics Biostructures AB
A103: Ace06, a Fully Human CLC BCMA/GPRC5D/CD3 Trispecific TCE Targeting Multiple Myeloma, Presented by Jinghua G., Shanghai AceMab Biotechnology Ltd.
A104: Fully Human DLL3/CD3 TCEs with Excellent Killing Potency Against Small Cell Lung Cancer (SCLC) Cells, Presented by See Heng W., Shanghai AceMab Biotechnology Ltd.
A105: Gen 3 Platforms and Affinity Maturation, Presented by Andrew B., Specifica, an IQVIA business
A106: In Vitro Approaches to Developing pH Antibodies, Presented by Andrew B., Specifica, an IQVIA business
A107: Potency-Attenuated Analogues of PNU-159,682 Provide GlycoConnect™/HydraSpace® ADCs with Improved Tolerability and Therapeutic Index, Presented by Marcel S., Synaffix - A Lonza company
A108: Construction and Characterization of Affibody-scFv Fusion Proteins Targeting FKBP51, Presented by Viktoria H., Technical University of Darmstadt
A109: The Effect of Target Specifying Protein Fusion on the Functionality of Anti-CD20-Based Tetravalent Bispecific Biologics, Presented by Omer G. & Dor I., Tel Aviv University
A110: Accelerating Discovery and Rational Engineering of Antibody Modalities Using Cryo-Electron Microscopy, Presented by Ieva D., Thermo Fisher Scientific
A111: Structural Basis for Activity Enhancement of Cancer Bispecific Antibody by Domain Rearrangement Revealed by Cryo-EM, Presented by Yoshikazu T., Tohoku University
A112: Design of Prodrug T Cell Engaging Bispecific Antibodies Employing T Cell Activation Molecules as Masks, Presented by Ryutaro A., Tokyo University of Agriculture and Technology
A113: Conformational Epitope Mapping of the Major Peanut Allergens, Presented by Almog B., Ukko, Inc.
A114: Development of Single-Domain Antibodies with Fluorescent and Luminescent Properties Using the Pichia pastoris Expression System, Presented by Aina G., Universidad Complutense de Madrid
A115: Development of a Novel Naïve scFv Rabbit Library, Presented by Santiago R., Universidad Complutense de Madrid
A116: A Novel Family of Cleavable Linkers for Antibody-Drug Conjugates, Presented by Indrealie LP., Universite de Strasbourg
A117: A Novel Lentiviral Production System to Minimise Transgene Expression in Producer Cells, Presented by Luke T., University College London
A118: AI-Based Protein Design and Validation, Presented by Bianca B., University Hospital Bonn
A119: CDCP1 - A Novel Target for CAR-T Cell Therapy in Prostate Cancer, Presented by Franziska S., University Hospital Bonn
A120: Applying Nanobody-Based Strategies in the Precision Therapy of Urological Cancers, Presented by Miriam S., University Hospital Bonn
A121: Impact of Sequence Representation on Machine Learning Models of Protein Expression, Presented by Yuxin S., University of Edinburgh
A122: Gb3-Targeting Lectibodies in Cancer Therapy, Presented by Jana T., University of Freiburg
A123: Pore-Forming Proteins: Can They Be Engineered to Selectively Form Pores on a Target Membrane?, Presented by Xiangling C., University of Groningen
A124: Exploring a Novel Enzyme Collection for Tumor Desialylation of Human Breast Cancer and Feline Mammary Carcinoma, Presented by Magda F., University of Lisbon
A125: Development of TROP-2-Targeting Recombinant Antibody-PROTAC Conjugates for Triple-Negative Breast Cancer, Presented by Rafaela M., University of Lisbon
A126: Targeted Desialylation of Tumor Cells: Unlocking a Novel Immunotherapeutic Approach, Presented by Alexandra O., University of Lisbon
A127: Spreadsheet DoE: A Tool for Optimising Protein Production and Characterisation, Presented by Elliott S., University of Liverpool
A128: Prediction of Concentration-Dependent Antibody Properties Using Interpretable Machine Learning, Presented by Na Young K., University of Michigan
A129: Design and Functional Characterization of Novel scFv× VHH Format of Biparatopic Antibody Against MtsA from Streptococcus pyogenes, Presented by Risa A., University of Tokyo
A130: Improving Mammalian Display Through Inclusion of IRES, Presented by Saara O., University of Turku
A131: Accelerating Drug Development by Molecular Imaging: Conjugation of Biomolecules for In Vivo Optical and Nuclear Imaging, Presented by Janik P., Vrije Universiteit Brussel
A132: VDU: A (Pre)GMP Facility for Small Scale Production of Biomolecules in Pichia pastoris, Presented by Hilde R., Vrije Universiteit Brussel
A133: Complementary Light Scattering Solutions for Protein Characterization, Presented by Nicolas M., Waters Corporation
A134: Towards Completely Computational Antibody Optimization, Presented by Ariel T., Weizmann Institute of Science
A135: Construction of Branched VHHs Complex Using SpyCatcher/Tag System, Presented by Koki M., Yamagata University
A136: Utilization of Precise Mutagenesis Library (PML) and High-Throughput (HTP) Fast Screening of Expression Biophysical-Properties Affinity (FASEBA) Screening Platform to Achieve High Affinity by Affinity Maturation, Presented by Payal R., ProBio, a subsidiary of GenScript Biotech Corporation
A137: Utilization of Naïve VHH Phage Display Library and Integrated Antibody Engineering Platform to Generate Antibody Leads for CAR-T Therapy, Presented by Payal R., ProBio, a subsidiary of GenScript Biotech Corporation
A138: Transgenic Llama Mice - A Fast and Flexible Single Domain Discovery Tool, Presented by Friedrich KN., Genovac
A139: Formulation Development of an HIV-Vaccine Protein, Presented by Mauricio M., NanoTemper Technologies Ltd.
A140: Predict Side Effect of Anti-CD28 Agonist Nanobodies In Silico, Presented by Yifei L., Technical University of Darmstadt
V1: Nanobody Tools for the Capture and Analysis of Cytokines and Immunoglobulins, Presented by Christian LW., ChromoTek GmbH
V2: Nanobody-Based Tools for In-Depth Research of Immuno-Oncology Targets, Presented by Sabrina W., ChromoTek GmbH
POSTER SESSION B: Wednesday (afternoon) – Thursday
*Posters 001-011 will be in both Poster Sessions and available Wednesday only.
*B001: Glyoxal Agarose as the Best Alternative for Covalent Antibody Coupling in Affinity Chromatography, Presented by Yaiza L., Agarose Bead Technologies
*B002: IgBlend: Unifying 3D Structure and Sequence for Antibody LLMs, Presented by Cedric M., AstraZeneca
*B003: Novel LCMS-Compatible icIEF Fractionation for Characterization of Innovator and Biosimilar mAbs, Presented by Jean-Francois B., Bio-Techne
*B004: Advancing Drug Discovery Using mMPS High-Throughput Synthesis Technology to Elevate Variant Library Precision, Presented by Ming D., GCATbio Co., Ltd.
*B005: Biology42: Generative Biologics Is an Advanced, AI-Powered Platform that Is Capable of Designing and Optimizing Different Types of Biologics, Including Peptides, Nanobodies, and Antibodies Tailored for Specific Targets, Presented by Andrei A., Insilico Medicine AI
*B006: K-One® Innovative Surface Chemistry: Revolutionizing Chip Functionalization and SPR Analysis of Biotherapeutics, Presented by Nicolas H., Kimialys
*B007: Unlocking Anakinra’s Potential: PEGylation for Prolonged Stability and Chain-length Modulation, Presented by Isilay G., Koc University
*B008: Broadly Inhibitory Human Monoclonal Antibodies Against Duffy Binding Protein II Variants Elicited by Natural Plasmodium vivax Infection, Presented by Piyawan K., Mahidol University
*B009: Combination of Peptide Mapping Analysis and SPR-Based Binding Kinetic to Identify Methionine Oxidation and Its Effect on the Biological Activity of IgG1 Antibody, Presented by Elvira L., Menarini Biotech S.r.l.
*B010: In Vivo Reprogramming of CAR-T Cells with LNP-Circular RNA Technology, Presented by Jing Z., Therorna, Inc.
*B011: A Clickable Antibody Design to Generate Antibody-Drug Conjugates (ADCs) in a Trojan Horse Manner, Presented by Nathanael R., Universitat Ramon Llull
B012: FAST - Enabling the Rapid Discovery and Creation of GPCR Agonist Antibodies, Presented by Monica S., Abalone Bio
B013: EpiScreen® 2.0 Immunogenicity Assays Utilizing EdU Proliferation and Activation Marker Analysis Provide Sensitive, Data-Rich Immunogenicity Assessments, Presented by Pearce C., Abzena
B014: Development of a Platform Approach to Identify the Most Functional and Developable Bispecific T-Cell Engager, Presented by Christopher S., Abzena
B015: TROCEPT: A Unique Adenovirus for In-Tumour Expression of Immunotherapies via Intravenous Delivery, Presented by Rita F., Accession Therapeutics Ltd.
B016: Overcoming Cell Line Development Inefficiencies and Streamlining the Clone Selection Process for Protein Biologic Production with the Solentim Ecosystem, Presented by Adam C., Advanced Instruments
B017: Engineering Bispecific T-Cell Engagers to Deplete Eosinophils for the Treatment of Severe Eosinophilic Asthma, Presented by Seul-Gi L., Ajou University
B018: Active Learning for Affinity Prediction of Antibodies, Presented by Alexandra G., AstraZeneca
B019: Exploring Log-Likelihood Scores for Ranking Antibody Sequence Designs, Presented by Talip U., AstraZeneca
B020: Automated Clone Screening System, Presented by Lutz E., Beckman Coulter Life Sciences
B021: Simple and Rapid Analytics for Protein Titer and Aggregation, Presented by Eligio I., Beckman Coulter Life Sciences
B022: Semi-Automated Extraction of Cell and Tissue Samples for Multi-Omic Analysis Using the Biomek i7 Hybrid Workstation, Presented by Antonia K., Beckman Coulter Life Sciences
B023: Implementing Sustainability in mAb Purification Workflows, Presented by Jean-Francois D., Bio-Rad Laboratories
B024: Viscosity Prediction of High-Concentration Antibody Solutions from All-Atom MD Simulations, Presented by Michaela B., Boehringer Ingelheim Pharma GmbH & Co. KG
B025: Polyoxyethylene Fatty Ethers as Alternative Surfactants in Biotherapeutic Formulations, Presented by Stefan C., Boehringer Ingelheim Pharma GmbH & Co. KG
B026: Formulatability Assessment to Evaluate Platform Fit of Molecules for Formulation Development, Presented by Kristina K., Boehringer Ingelheim Pharma GmbH & Co. KG
B027: Complex Protein Format Development: A Deep Dive into Understanding Impact on Process Development, Presented by Petra V., Boehringer Ingelheim Pharma GmbH & Co. KG
B028: HT-SPR Evaluation of Fc Gamma Receptor Binding Using Carterra LSA-XT, Presented by Christian G., Carterra, Inc.
B029: Large-Scale Characterization of Drug Candidates Against Transmembrane Receptors Using HT-SPR, Presented by Andrew G., Carterra, Inc.
B030: Phagekine Directed Evolution: Discovery and Optimization of Interleukin-2-Derived Immunotherapeutics, Presented by Gertrudis R., Center of Molecular Immunology
B031: Constrained Peptide Modeling, Conformational Analysis and Property Predictions, Presented by Purvi G., Chemical Computing Group
B032: Structure-Based Charge Calculations for Predicting Properties and Profiling Antibody Therapeutics, Presented by Nels T., Chemical Computing Group
B033: Crowdsourcing Targets for Antibody Panning: Depositing NGS Data into the Public Domain, Presented by Harmen V., Cradle Bio
B034: A Streamlined Drug Discovery Platform for the Production and Characterization of Protein Biologics and Antigens, Presented by Kevin S., CRELUX, a WuXi AppTec Company
B035: Epitope Mapping Case Studies by Deep Mutational Scanning, Presented by Hugo G., Deeptope
B036: Modulation of Antibodies' Fc Fragment Interaction with Fc Receptors by Deep Mutational Scanning, Presented by Fabien Q., Deeptope
B037: Discovery and Characterization of Biased Agonist and Antagonist Anti-hCCR5 Antibodies Using 3rd Generation ebBRET Biosensors, Presented by Guilhem D., Domain Therapeutics NA, Inc.
B038: Real-Time Screening of Protein Stability at Liquid-Liquid Interfaces in a Microfluidic Device, Presented by Dominik Z., ETH Zurich
B039: Optimization of Antibody Production: A Study Using Nalgene 5L Angled Bottom Shake Flasks with the ExpiCHO Expression System, Presented by Silvana A., FairJourney Biologics SA
B040: Antibody Discovery and Characterization: A Multidimensional Approach for Next-generation Therapeutics, Presented by Joana Q., FairJourney Biologics SA
B041: Machine Learning Guided Interaction Analysis, Presented by Sean D., Fluidic Sciences Ltd.
B042: Establishment of Rabbit Monoclonal Antibodies Against Membrane Proteins Using New Single B Cell Screening Technology, Presented by Albert Z., FUJIFILM Wako Chemicals Europe GmbH
B043: Harnessing the Synergy Between Biophysics and Structural Biology to Drive Drug Discovery, Presented by Leopold T., Galapagos NV
B044: Effect of N-Terminal Amino Acid Sequence on the Protein Synthesis Using a Reconstituted Cell-Free Protein Synthesis System, Presented by Takashi K., Genefrontier
B045: Optimizing Antibody Lead Identification: A High Throughput Sequencing and Synthesis Solution, Presented by Hans H., GENEWIZ from Azenta Life Sciences
B046: Rapid Quality Assessment of Therapeutic Monoclonal Antibodies Through Automated Middle-Level Mass Spectrometry, Presented by Kristina S., Genovis
B047: A Novel Enzyme for Efficient Digestion of Hinge-Mutated Antibodies, Presented by Philip W., Genovis
B048: Leveraging GenScript’s DNA Mutant Libraries for AI-Based Epitope-Specific Antibody Drug Design, Presented by Xing G., GenScript USA, Inc.
B049: Targeted Delivery of IL-2 to CD8[+] T Cells by GI-108 via Cis-Binding Mechanism Enhances Anti-Tumor Immunity Through the Expansion of Tumor-Specific CD8[+] T Cells, Presented by Kayoung S., GI Innovation
B050: Membrane, Resin, and Impact to Product: Overcoming Barriers to Adopting Membrane Technology by Demonstrating Protein A Affinity Capture Step Product Quality and Process Characteristic Similarity, Presented by Jeffrey C., W. L. Gore & Associates, Inc.
B051: ML-Guided Epitope Steering and Antibody Optimization with Mammalian Display Generates a Diverse Panel of CD3 T-Cell Engagers, Presented by Martin b., iBio, Inc.
B052: Development of a High-Titer Bi-Paratopic Tetravalent Diabody-Fc-Fab: Using the IcoCell® Line, Design for Manufacturability and Modern DoE, Presented by Ilja G., Icosagen
B053: Managing Discovery and Early Characterization Workflows of T Cell Receptors for Biotherapeutic Use in an Integrated Data System, Presented by Lina B., Immatics Biotechnologies GmbH
B054: Affinity Maturation of a TCR Targeting the Tumor Stroma Antigen COL6A3 Increases Sensitivity and Specificity, Presented by Thomas T., Immatics Biotechnologies GmbH
B055: High Throughput Epitope Mapping and Screening in Live Cells, Presented by Hetal M., Immuto Scientific
B056: ANTIPASTI: Interpretable Prediction of Antibody Binding Affinity Exploiting Normal Modes and Deep Learning, Presented by Kevin M., Imperial College London
B057: STEAP1 Targeting CAR-T Cells Locally Expressing Collagen-Binding IL-12 for Advanced Prostate Cancer, Presented by Koichi S., Imperial College London
B058: Preferred Left-Handed Conformation of Glycyls at Pathogenic Sites, Presented by Purva M., Indian Institute of Science Education and Research, Mohali
B059: Enhanced Plasmid Production: Achieving a 21-Fold Increase in Plasmids per Liter with 88.5% Supercoiled DNA, Presented by David LP., Infors AG
B060: Accelerating VHH Lead Candidate Panel Generation Through High-Throughput Early Triaging of Optimal B Cell Clones, Presented by Arthur K., IPA (ImmunoPrecise Antibodies)
B061: Amplifying the Therapeutic Potential of Rabbit-Derived Antibodies by an Advanced, Multi-Parametric Humanization Approach for Single-Step Engineering, Presented by Ilse R., IPA (ImmunoPrecise Antibodies)
B062: Pharmacokinetic Profiling of Albumin-Associated Drugs Using a Humanized Mouse Model with Human Albumin and FcRn, Presented by Adriano F., Jackson Laboratory
B063: Next-Generation Humanized Models for Evaluating Immunomodulatory Molecules In Vivo, Presented by Ralph G., Jackson Laboratory
B064: Humanized FcRn Models to Assess the Pharmacokinetic Profile of Therapeutic Antibodies, Presented by Philip G., Jackson Laboratory
B065: Transforming Tumor Research: Engineering MHCs as Versatile Reagents, Presented by Xiaoyuan R., KactusBio, Inc.
B066: GPCR VLPs & Nanodiscs for Drug Discovery, Presented by ManHee S., KactusBio, Inc.
B067: The FUT8 KO SURE CHO-M Cell Line™ for Production of Afucosylated Therapeutic Antibodies, Presented by Louis D., KBI Biopharma
B068: New Transposase Integration in SUREtechnology Platform™ Takes High-Performance Clones to the Next-Level, Presented by Eva G., KBI Biopharma
B069: Recombinant Production of Bovine Serum Albumin (BSA) in Yeast, Presented by Matilde D., Levprot Bioscience
B070: Exploiting Auto-Induction by Carbon Source Limitation to Improve Space-Time-Yields of Recombinant Protein Production in E. coli, Presented by Karlheinz F., Lonza
B071: Novel Synthetic Production Phase Promoter for Enhanced Titre, Product Quality and Expression Stability in CHO Cells, Presented by Yusuf J., Lonza
B072: Clone-Wise Biomarker Discovery Enabled Through Single-Cell RNA Sequencing, Presented by Pavle V., Lonza
B073: A Novel IL23R-IL12R Cytokine Switch Receptor for Solid Tumor Cell Therapy, Presented by Dominic S., Ludwig Maximilians University
B074: An Afucosylated Monoclonal Antibody Increases In Vitro Opsonophagocytic Killing of Enterococcus faecalis Bacteria, Presented by Enisa S., Ludwig Maximilians University
B075: Case Study: Assessing Innovator vs. Biosimilar mAb Stability to Minimize Immunogenic Risk, Presented by Edward F., Malvern Panalytical
B076: Next-Generation Bioanalytical Instrument for Drug Discovery and Life Sciences, Presented by Amanda P., Malvern Panalytical
B077: Unleashing the Power of Perfusion: A Breakthrough in Cell Line Development for Intensified Processes, Presented by Vincent B., MilliporeSigma
B078: Effect of Transport and Storage on the Stability of Endometrial Cancer Biomarkers in Processed and Unprocessed Uterine Aspirate Samples, Presented by Javier C., MiMARK Diagnostics
B079: A Method for High-Throughput Screening of Monoclonal Antibody Internalization Using a DNA/Protein Molecular Staple, Presented by Lara M., Monash University
B080: Discovery of T-Cell Receptor Mimic Antibody Derived T-Cell Engager, Presented by Erica F., Nona Biosciences
B081: Enabling Fast Discovery of VHHs for Radioligand Therapy, Presented by Alexandra L. & Luca S., Novartis Pharma AG
B082: Cell Free Expression of E3 Ubiquitin Ligases to Accelerate Target Protein Degradation Studies, Presented by Suzanne F., Nuclera
B083: Screen, Scale, Capture, Characterize: Rapid Protein Production and Characterization of Drug-Target Interactions, Presented by Chiara G., Nuclera
B084: AbiProt: A Breakthrough Technology for Identification of Antigenic Regions on Challenging Transmembrane Proteins, Presented by Anaswara A., Oblique Therapeutics AB
B085: High Throughput Hydrophobicity and Polyreactivity Assays for 6His-Tagged Proteins, Presented by Aris P., PAIA Biotech GmbH
B086: Establishing an Untargeted Metabolomics Workflow for Analysis of Spent Media by LC-MS, Presented by Paul G., Pharmaron
B087: Directed Luck®: Transposase Targeting and Transposon Design Push Expression Beyond Limits, Presented by Thomas R., ProBiogen
B088: Machine-Learning Guided Engineering of Nivolumab for Superior Stability and Solubility, Presented by Norio H., RevolKa Ltd.
B089: Application of Gene Editing Technologies to Improve Biotherapeutic Manufacturing, Presented by Neha M., Revvity
B090: Integration of Next-Generation Transposon Vectors with Novel Host Cell Lines, Presented by Alex O., Revvity
B091: CHOSOURCE™ ADCC+ Cell Line for Enhanced Therapeutic Potency, Presented by Jesus Z., Revvity
B092: 2D-CEX-FcRn-MS to Study Structure/Function Relation of mAb Charge Variants, Presented by Thomas M., RIC Biologics
B093: Discovery and Characterization of Antibodies Against Challenging Membrane Protein Targets Using Salipro® Nano-Membrane Particles, Presented by Peter J., Salipro Biotech AB
B094: Mechanistic Investigation of Antibody FcRn Interactions Using Confocal Microscopy, Presented by Tobias B., Sanofi
B095: Employing Automation and Machine Learning to Innovate Sartorius 4Cell® CHO Platform Cell Line Development Service, Presented by Jimit S., Sartorius Stedim Cellca GmbH
B096: CHOice for Success: Mastering Media-Feed Screening and Analysis, Presented by Dennis K., Sartorius Xell GmbH
B097: Development of Structural Analysis Services of Protein-Ligand Complexes in “Fast Track” Mode, Presented by Ekaterina B., Selvita
B098: Optimizing Freeze-Thaw Stability of Monoclonal Antibodies: Scale-Down Approaches, Presented by Andreia D., Smartfreez
B099: How to Use Cold-Accelerated Studies to Model Aggregation of Antibodies During Storage, Presented by Miguel R., Smartfreez
B100: High Throughput Functional Single Cell Analysis for Antibody Discovery and Cell Therapy, Presented by Yoshiharu H., Sony Corporation
B101: AIntibody: An Experimentally-Validated In Silico Antibody Discovery Challenge, Presented by Frank E., Specifica, an IQVIA business
B102: A New Convenient Tool to Analyse Protein Glycosylation Based on FT-IR Spectroscopy, Presented by Allison D., Spectralys Biotech SRL
B103: Picodroplets for Biologics Discovery and Cell Line Development: Accelerating the Discovery and Development Process, Presented by Maryam A., Sphere Fluidics
B104: Detecting Particles for Root Cause Analysis: Distinguishing and Quantifying Surfactant Degradation Products, Silicone Oil and Protein Aggregates, Presented by Laura P., Spheryx, Inc.
B105: Cryo-EM for Structurally Enabled Therapeutic Antibody Development Against GPCRs, Presented by Joshua G., Sygnature Discovery
B106: Efficient Generation, B Cell Isolation, and High-Throughput Production for Monoclonal Antibodies, Presented by Giuseppe R., Takis Srl
B107: Masking of Antibodies Using an Calmodulin-Derived Affinity Lock Approach, Presented by Adrian B., Technical University of Darmstadt
B108: Enhanced Targeting Approach for NKp30-Based NK Cell Engagers, Presented by Lexane F., Technical University of Darmstadt
B109: Using Protein Geometry to Optimize Cytotoxicity and the Cytokine Window of a ROR1 Specific T Cell Engager, Presented by Felix G., Technical University of Darmstadt
B110: Taming IL 12: Engineering of Bispecific Antibody Based IL 12 Mimetics with Biased Agonism Capacities, Presented by Britta L., Technical University of Darmstadt
B111: Engineering Bispecific Antibodies Targeting CD89 for Innate Immune Cell-Mediated Tumor Eradication, Presented by Felix M., Technical University of Darmstadt
B112: A Genetic Strategy for the Conversion of Therapeutic mAbs into Immune Cell Recruiting Bispecifics, Presented by Paul P., Technical University of Darmstadt
B113: Patterns of Conformational, Colloidal and Time-Dependent Stability for the Categorisation of Therapeutic Monoclonal Antibodies, Presented by Deniz S., Technical University of Munich
B114: Detective’s Toolbox: Investigating Polysorbate Degradation Pathways, Presented by Michal R., ten23 health AG
B115: Power Meets Precision | with Expi™ Protein Expression Systems and GeneArt HTP Antibody Production, Presented by Richard A., Thermo Fisher Scientific
B116: Machine-Learning-Assisted Multiple Maturation of Antibody Fragment: Simultaneous Improvement of Target-Binding, Bacterial Expression, and Thermal Stability, Presented by Mitsuo U., Tohoku University
B117: Employing Membrane-Bound E3 Ligases for Targeted Degradation of Cell Surface Proteins Using Heterobispecific Antibodies (SureTACs), Presented by Michiel B., Universitair Medisch Centrum Utrecht
B118: Engineering Recombinant Human Vaults to Target Cancer Stem Cells, Presented by Roger FP., Universitat Autònoma de Barcelona
B119: Optimization of Protein Solubility and Recovery of Precipitated Proteins, Presented by Mercedes M., Universitat Autònoma de Barcelona
B120: Aggrescan4D: Structure-Informed Analysis of pH-Dependent Protein Aggregation, Presented by Giulia P., Universitat Autònoma de Barcelona
B121: A Novel Structure-Driven Strategy for Parkinson's Disease Immunotherapy, Presented by Marc EA., Universitat Autònoma de Barcelona
B122: Validating Macrophage Targets for CAR-M Delivery, Presented by Sam D., University College London
B123: AsEP: Benchmarking Deep Learning Methods for Antibody-Specific Epitope Prediction, Presented by ChuNan L., University College London
B124: Tuning ProteinMPNN to Reduce Protein Visibility via MHC Class I Through Direct Preference Optimization, Presented by Hans-Christof G., University of Edinburgh
B125: Cats naturally infected with SARS-CoV-2: A potential source for developing antibodies against COVID-19 and future outbreaks, Presented by Isa M., University of Lisbon
B126: Generation of Biepitopic Antibodies with Intrinsic Agonism for Activating Tumor Necrosis Factor Receptors, Presented by Namir K., University of Michigan
B127: Ultra-Efficient and Long-Lived Delivery of Cytokines to the CNS, Presented by Wade K., University of Michigan
B128: Negative Data Composition Affects Machine Learning Generalization and Biological Rule Discovery, Presented by Aygul M., University of Oslo
B129: Design, Stabilize, Design: Using a Variety of Machine Learning Tools to Create De Novo TLRs and Their Binders, Presented by Cameron C., University of Washington
B130: Evolving E3 Ligase Towards Recognising Novel Substrates for Targeted Protein Degradation, Presented by Sasha M., University of Zurich (UZH)
B131: Harnessing Yeast for Antibody Drug Discovery and Development, Presented by Royan AS., VIB-UGent Center for Medical Biotechnology
B132: Examples of Qualitative and Quantitative Potential of Intact Protein LC-MS, Presented by Waltteri H., VTT Technical Research Centre of Finland
B133: High Throughput Cysteinylation Screening at mAb Subunit Level Using LC-MS Monitoring Workflow , Presented by Guillaume B., Waters Corporation
B134: Simple and Automatable Sample Preparation for Tryptic Peptide Mapping with the PeptideWorks Kit, Presented by Antonia W., Waters Corporation
B135: This, That, and the Other – Combining Primary, Secondary, and Tertiary Signals with Immune Cell Engagers to Supercharge Anti-Tumor Immunity, Presented by Winfried E., WuXi Biologics
B136: Optimizing Bispecific Antibody Production for Higher Titer and Purity Across Diverse Formats, Presented by Lorenz F., WuXi Biologics
B137: Generation and Engineering of Potent Single Domain Antibody-Based Bispecific IL-18 Mimetics, Presented by Laura U., Technical University of Darmstadt
B138: Targeting LIFR as a Novel Therapeutic Approach for Fibrosis and Cancer Immunotherapies, Presented by Yunju J., Kyung Hee University
B139: Seamless Integration of a Universal Epitope into Recombinant TCRs for Tagging and Tracking of TCR-T Cells Expressing 3S TCRs, Presented by Kanuj M., Medigene Immunotherapies GmbH
B140: On-Target – Prioritizing Specificity During T Cell Engager Discovery Against Peptide:HLA Antigens, Presented by Mark T., Imuno Therapeutics
V1: Nanobody Tools for the Capture and Analysis of Cytokines and Immunoglobulins, Presented by Christian LW., ChromoTek GmbH
V2: Nanobody-Based Tools for In-Depth Research of Immuno-Oncology Targets, Presented by Sabrina W., ChromoTek GmbH